Abivax has surged nearly 1,900% this year after a blockbuster Phase 3 readout transformed it from a speculative biotech into a strategic asset. With an $11 billion market cap, takeover chatter reportedly involving Eli Lilly has introduced a valuation floor, while upcoming Crohn disease data could unlock further upside.